Predictors of pathologic complete response in triple‑negative breast cancer treated with neoadjuvant chemotherapy: a systematic review and meta-analysis
Authors:
Open Access
- 17 May 2026
- journal article
- review article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Abstract
Preoperative neoadjuvant chemotherapy (NAC) is a commonly employed treatment strategy for triple-negative breast cancer (TNBC). Various clinical factors may influence the likelihood of achieving a pathological complete response (pCR) following NAC. This study conducted a meta-analysis to identify factors associated with pCR to inform clinical decision-making. EMBASE, PubMed, WOS, Scopus databases were selected as the information sources to identify studies published before July 1, 2025. Predefined inclusion and exclusion criteria were applied, and the quality of included studies was assessed. Commonly reported factors were subjected to meta-analysis. Thirteen studies published between 2011 and 2025 were included, with eight published before 2020 and five thereafter. Seven potential influencing factors were analyzed, including individual characteristics, pathological features, and serum biomarkers. The pooled results indicated that clinical tumor stage (OR (odds ratio) = 0.35, 95% CI: 0.21–0.59, p = 0.032), Ki-67 expression (OR = 2.91, 95% CI: 1.64–5.16, p < 0.001), BRCA1/2 mutation status (OR = 1.95, 95% CI: 1.04–3.66, p = 0.037), and neutrophil-to-lymphocyte ratio (NLR) (OR = 5.61, 95% CI: 2.05–15.34, p < 0.001) were significantly associated with pCR. In contrast, age at diagnosis, histological grade, and nodal status were not statistically significant predictors. The likelihood of achieving pCR in TNBC patients undergoing NAC is significantly associated with clinical stage, Ki-67 expression, BRCA1/2 mutation status, and NLR. These factors should be evaluated prior to chemotherapy to help tailor treatment strategies and optimize therapeutic outcomes.Keywords
This publication has 38 references indexed in Scilit:
- Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and ImmunotherapyCancer Treatment Reviews, 2024
- Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancerBreast Cancer, 2023
- Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancerBreast Cancer Research and Treatment, 2022
- Ki-67 protein as a tumour proliferation markerClinica Chimica Acta, 2019
- Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patientsThe Breast, 2017
- Molecularly targeted therapies for metastatic triple-negative breast cancerBreast Cancer Research and Treatment, 2013
- CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patientsMedical Oncology, 2010
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patientsCancer Chemotherapy and Pharmacology, 2010
- The Ki-67 protein: From the known and the unknownJournal of Cellular Physiology, 2000